aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of “Hold” from Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has earned a consensus rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $17.00.

Several research firms have weighed in on ATYR. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings raised shares of aTyr Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Freedom Capital upgraded aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th.

aTyr Pharma Stock Up 3.4%

Shares of ATYR stock opened at $0.49 on Tuesday. The firm has a 50 day moving average of $0.51 and a 200-day moving average of $0.72. The company has a market cap of $48.01 million, a price-to-earnings ratio of -0.67 and a beta of 0.52. aTyr Pharma has a 52 week low of $0.40 and a 52 week high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Analysts anticipate that aTyr Pharma will post -0.66 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Paul Schimmel purchased 100,000 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were acquired at an average price of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director owned 779,143 shares in the company, valued at approximately $389,571.50. The trade was a 14.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.75% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds and other institutional investors have recently modified their holdings of ATYR. California State Teachers Retirement System bought a new position in shares of aTyr Pharma in the 2nd quarter worth $28,000. Renaissance Technologies LLC bought a new stake in aTyr Pharma during the 1st quarter valued at $32,000. ADAR1 Capital Management LLC increased its stake in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after purchasing an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new position in aTyr Pharma during the fourth quarter worth $41,000. Finally, Legal & General Group Plc acquired a new position in aTyr Pharma during the second quarter worth $49,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.